Dead Cells: The Queen And The Sea if its not the last DLC after all, then all the better (pic: Motion Twin)
The third, but not necessarily final, paid-for DLC for Dead Cells is the first major release of 2022 and just as good as youd expect.
Way back in the early history of video games there was a game called Rogue. Released in 1980, it was a dungeon crawler where each time you died you started again at the beginning, right from scratch. Its the kind of brutality players modern players arent used to but its design choices have inspired numerous developers since the turn of the millennium, giving birth to the still popular roguelike genre.
Even though Dead Cells, which received its most recent piece of DLC this month, is a roguelike, it also has strong Metroidvania leanings. Like its namesakes, Metroid and Castlevania, new powers and equipment let you reach previously inaccessible areas in levels youve already played. Its a way of hiding secrets in plain sight, tempting you to progress so you can explore areas that you could see, but that remained tantalisingly out of reach.
In 2017, when Dead Cells entered early access on Steam, players discovered a small, tightly designed 2D Metroidvania game, with short levels, pixel perfect animation, and a roguelike keenness to teach you through repeatedly killing you. Little did anyone know, least of all developer Motion Twin, that the coming five years would see the game morph into a six million selling behemoth.
Each of Dead Cells immaculate, procedurally generated levels comprises its own biome, complete with their own delightful parallax scrolling backgrounds, scenery, and enemies. Feeling your way around the map, you soon find out which biome leads where, letting you plan a route through areas and past enemies that you at least have a chance of beating.
Before it entered full release in 2018, the original Dead Cells had already gained the Time Keeper boss as DLC, as well as the Slumbering Sanctuary biome and the dreaded Forgotten Sepulchre, a level shrouded in a darkness that will kill your character a nameless, headless former prisoner if hes left exposed to it for too long. It also gained mutations, the games perk system that you unlock in the corridor-like anterooms that preface each biome.
The final pre-launch innovation was the addition of boss stem cells, which you earn by defeating the Hand of the King, the games final boss. Each stem cell cranks up the difficulty, reshuffles the connections between levels, and most significantly, alters the enemies you face in each area. Stem cells not only keep the game fresh but add a degree of challenge that gives Dead Cells a longevity measured in hundreds of hours.
Since then, the updates have arrived thick and fast. Fresh biomes, new enemies, more weapons, bigger bosses, different mutations, and continual rounds of nerfs and buffs to maintain balance amongst the games rapidly expanding bestiary and armoury. Always engaged with the games obsessive fanbase, the developers have ensured the onslaught of new material, and frequently requested quality of life improvements, has never let up.
Perhaps the most surprising element of all this is that almost every update and DLC has been delivered free. Even post-2019, when development switched to Evil Empire, a spin-off studio formed specifically to support the title, only two of its DLCs have been paid-for, a sustained feat of generosity rarely matched in the modern era.
The latest update, The Queen And The Sea, is only the third one you have had to pay for, and is intended as the finale of the narrative arc that runs between all three paid-for expansions.
After downloading it, a tentacle drops off a letter right at the beginning of Prisoners Quarters, the games first level, acting as a signpost for a set of clues that will lead you to a giant, heavily armoured prawn who gives you possibly the updates most powerful weapon: the Leghugger, a sidekick that feeds on enemies, eventually eating enough of them to evolve into its even more powerful adult state.
The armoured shrimp also leaves you a key to the Lighthouse, which pops open a door in the last level, High Peak Castle, where you can set sail for the Infested Shipwreck, the first of two new biomes. Its here that youll discover not all adult Leghuggers are friendly, some in fact want to eat you just as much as your new buddy enjoys devouring foes.
Make it through the Shipwreck and youll face the new boss, The Queen. She starts by chasing you up through the rickety structure of the Lighthouse, which is consumed by flames in her wake, meaning speed is very much of the essence. Get to the top and its time to fight her, replacing the final battle with the Hand of the King.
Along with the new boss and biomes come a slew of new weapons, from the Maw of the Deep (a shark you use to swing at enemies before hurling it at them jaws first) to the Hand Hook (a distinctly pirate-y way to lay waste to foes) and the Scavenged Bombard (a squat little cannon that does a lot of damage, but only works when youre standing right next to it).
The sheer number of possible routes enabled by the procedural generation, and the multiplicity of final bosses make, ensures that Dead Cells is a different game every time you play it. Thats something thats only slightly attenuated by using Custom Mode, which lets you exclude weapons, powers, and mutations you dont fancy using.
Although Motion Twin hasnt said what its paid-for plans are beyond The Queen And The Sea, it has already promised lots more free DLC throughout 2022 which suggests an embarrassment of riches without paying a penny more. After more than three years of non-stop development, Dead Cells stands as one of the best indie games of all time and its only getting better.
In Short: Motion Twins winning take on 2D Metroidvania roguelikes is kept alive by another excellent DLC expansion.
Pros: Two well designed new levels to explore, one of which is completely different from anything thats come before, adds fresh routes through the game and a new final battle.
Cons: If you dont enjoy the punishing nature of roguelikes, or ultra-fast 2D actioners, this is unlikely to dissuade you from that view.
Score: 9/10
Formats: PlayStation 4 (reviewed), Xbox One, Nintendo Switch, PC, iOS, and AndroidPrice: 3.99 (9.49 for all three paid-for DLCs or 26.99 with base game as well)Publisher: Motion TwinDeveloper: Evil EmpireRelease Date: 6th January 2022Age Rating: 16
By Nick Gillett
Email gamecentral@metro.co.uk, leave a comment below, and follow us on Twitter.
MORE : Dead Cells: Fatal Falls DLC review falling in love again
MORE : Dead Cells: The Bad Seed DLC review growing content
MORE : Dead Cells review random inspiration
Follow Metro Gaming on Twitter and email us at gamecentral@metro.co.uk
For more stories like this,check our Gaming page.
Read the original:
Dead Cells: The Queen And The Sea DLC review - water ending - Metro.co.uk
- Adult Stem Cells: What They Are and What They Do - February 6th, 2025
- What Are Adult Stem Cells and Are They Right for You? - February 6th, 2025
- Stem Cell Program | Adult Stem Cells - Boston Children's Hospital - February 6th, 2025
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
Recent Comments